Quantcast

Latest Decision Resources Group Stories

2014-09-23 12:28:21

However, Surgeons Continue to Question the Cost-Benefits of the Technology, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 23, 2014 /PRNewswire/ -- Decision Resources Group finds that the United States market for surgical navigation systems will gradually expand due to demand for minimally invasive surgery and growing awareness of the benefits of surgical navigation. As a result, the U.S. surgical navigation system market will generate over $260 million by 2023....

2014-09-22 12:26:18

Opportunities Will Be Driven By Projected Annual Growth Trend of 11.3 Percent Over the Next Five Years, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 22, 2014 /PRNewswire/ -- Decision Resources Group finds that by the end of 2014, the Chilean pharmaceutical market is expected to be worth $2 billion (U.S. dollars), increasing at a compound annual growth rate of 11.3 percent over the next five years (to 2018). This growth comes as Chile experienced GDP growth of...

2014-09-18 12:29:43

The Highest Percentage of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next One to Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that at one year post-launch in the United States, 54 percent of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF inhibitor Tafinlar for BRAF-mutation-positive unresectable or metastatic melanoma, compared with 49...

2014-09-18 12:29:19

Fovista and Abicipar Pegol Will Need to be Priced Competitively to Current Agents to Garner Favorable Tier Placement, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that Regeneron's Eylea, the most recently launched anti-vascular endothelial growth factor (VEGF) agent for wet AMD, is equally likely to be covered on commercial and Medicare Advantage plans as Genentech's Lucentis, which is the standard of care...

2014-09-18 12:27:44

Several Emerging Therapies Will Expand Treatment Armamentarium for Unresectable Locally Advanced or Metastatic Gastric Cancer, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that the gastric cancer market will grow exponentially from over $1.1 billion in 2013 to nearly $3.8 billion by 2023. Fuelling this growth will be the launch of five targeted therapies for unresectable locally advanced and metastatic...

2014-09-17 12:27:46

SGLT-2 Inhibitors Will Be the Fastest-Growing Drug Class Over the 2013-2023 Forecast Period, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 17, 2014 /PRNewswire/ -- Decision Resources Group finds that as physicians continue to adopt a more individualized approach to patient care, branded type 2 diabetes therapies continue to experience increased use despite attempts by payer and reimbursement authorities to limit use of these more expensive drugs. As the robust...

2014-09-17 12:25:34

Improved Efficacy and Lower List Price than the Anti-TNFs Will Be the Key Drivers for Prescribing of Emerging Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 17, 2014 /PRNewswire/ -- Decision Resources Group finds that among Crohn's disease/ulcerative colitis (CD/UC) patients eligible for biologic therapy, only a proportion of patients currently receive a biologic. Surveyed gastroenterologists cite patients' discomfort with biological therapy as the...

2014-09-16 12:30:41

Rheumatologists Report that the Vast Majority of RA Patients Who are Candidates for Biologic Treatment Receive a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 16, 2014 /PRNewswire/ -- Decision Resources Group finds that the percentage of rheumatoid arthritis (RA) patients treated with a biologic agent by rheumatologists has remained relatively constant since 2012 in the major European markets (France, Germany, Italy, Spain and the United Kingdom)....

2014-09-16 12:30:11

The Imminent Entry of Biosimilars Will Constrain Sales of Branded Biologics and Premium-Priced Emerging Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 16, 2014 /PRNewswire/ -- Decision Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion in 2013 to over $18.2 billion in 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. TNF-alpha inhibitors...

2014-09-15 16:28:08

Key Digital Opportunities for Med Device Brands Highlighted in New Manhattan Research Study from Decision Resources Group BURLINGTON, Mass., Sept. 15, 2014 /PRNewswire/ -- Decision Resources Group's new Manhattan Research study, Digital MedTech Physician(TM) 2014, finds that online information and other value-added services are emerging ways for brands to differentiate their offering and support physicians. Physicians who are responsible for medical device purchasing decisions rely on...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related